List of Excipients in Branded Drug ZIANA

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Bausch Health US LLC	ZIANA	clindamycin phosphate and tretinoin	99207-300	ANHYDROUS CITRIC ACID
Bausch Health US LLC	ZIANA	clindamycin phosphate and tretinoin	99207-300	BUTYLATED HYDROXYTOLUENE
Bausch Health US LLC	ZIANA	clindamycin phosphate and tretinoin	99207-300	CARBOMER HOMOPOLYMER TYPE A
Bausch Health US LLC	ZIANA	clindamycin phosphate and tretinoin	99207-300	EDETATE DISODIUM
Bausch Health US LLC	ZIANA	clindamycin phosphate and tretinoin	99207-300	GLYCERIN
Bausch Health US LLC	ZIANA	clindamycin phosphate and tretinoin	99207-300	METHYLPARABEN

ZIANA Excipient Strategy, Formulation Economics, and Commercial Opportunities

Last updated: October 30, 2026

ZIANA is a topical combination gel containing clindamycin phosphate equivalent to 1% clindamycin and tretinoin 0.025% for acne vulgaris. Its commercial value is tied less to active-ingredient exclusivity than to vehicle performance, tolerability, preservative control, packaging, and regulatory evidence for topical-equivalence claims. The main excipient opportunity is to improve irritation, stability, sensory characteristics, and dispensing while preserving the product’s established clinical profile.

What is ZIANA and which excipients does it contain?

ZIANA Gel is an aqueous topical formulation with clindamycin phosphate and tretinoin. The labeled inactive ingredients are glycerin, carbomer 980, methylparaben, polysorbate 80, disodium edetate, citric acid, sodium hydroxide, and purified water.[1]

Component	Functional role	Commercial relevance
Purified water	Continuous phase	Requires microbial control and compatible packaging
Glycerin	Humectant and solvent aid	Supports skin feel and reduces drying from the aqueous gel
Carbomer 980	Gelling and rheology agent	Controls viscosity, suspension, spreadability, and residence time
Methylparaben	Preservative	Enables multidose packaging but may create consumer and regulatory positioning issues
Polysorbate 80	Surfactant and solubilization aid	Helps distribute hydrophobic tretinoin and supports uniformity
Disodium edetate	Chelating agent	Reduces metal-catalyzed degradation and supports preservative performance
Citric acid	pH adjustment and buffering	Helps control active stability and skin compatibility
Sodium hydroxide	Neutralization and pH adjustment	Activates carbomer viscosity and sets final pH
Clindamycin phosphate	Antibiotic active	Requires antimicrobial-resistance and labeling controls
Tretinoin	Retinoid active	Drives photostability, irritation, and packaging requirements

The formulation is commercially important because the two active ingredients present different technical problems. Clindamycin phosphate is water-compatible but can be affected by pH and hydrolytic conditions. Tretinoin is poorly water-soluble and sensitive to light, oxygen, and formulation environment. The excipient system must therefore reconcile aqueous delivery with retinoid dispersion and stability.

What formulation strategy does ZIANA use?

ZIANA uses a carbomer-based aqueous gel. Carbomer 980 provides the three-dimensional polymer network that gives the product its viscosity and skin residence. Sodium hydroxide neutralizes the polymer, while citric acid supports pH adjustment. The resulting gel must be viscous enough to remain on the skin but spreadable enough for facial application.

Polysorbate 80 is a key formulation component. It supports dispersion of tretinoin in the aqueous vehicle and reduces the risk of visible drug crystallization or nonuniform dosing. Its use also creates development constraints because surfactants can influence irritation, preservative partitioning, polymer viscosity, and the release of poorly soluble compounds.

Glycerin contributes humectancy and can moderate the drying sensation associated with topical acne treatment. It can also affect water activity, viscosity, and sensory properties. Methylparaben and disodium edetate form part of the microbial-control strategy, although preservative performance must be demonstrated in the final container rather than inferred from the ingredient list.

Which excipient attributes control product performance?

Rheology and drug uniformity

Carbomer grade, neutralization level, mixing energy, and order of addition can materially affect viscosity and content uniformity. Excessive shear may alter polymer structure. Inadequate neutralization can produce a thin product with poor residence time. Excessive viscosity can impair spreading and may alter the rate at which the active ingredients leave the vehicle.

A generic or reformulated product should characterize:

• Low-, medium-, and high-shear viscosity
• Yield stress and spreadability
• Drug content uniformity across the container
• Tretinoin particle or droplet-size distribution
• Clindamycin and tretinoin release
• Physical stability under temperature and light stress

pH control

pH affects carbomer viscosity, clindamycin phosphate stability, preservative performance, and skin tolerability. The target range should be established through formulation development rather than copied solely from the reference product. A pH shift can cause a visible change in viscosity or alter tretinoin degradation.

Citric acid and sodium hydroxide provide adjustment capacity but do not necessarily create a strong buffer. The finished product requires pH monitoring during accelerated and long-term stability studies.

Photostability and oxidation

Tretinoin is sensitive to light. The formulation and container should be evaluated together under ICH photostability conditions and with real-use exposure. A transparent tube, poorly protected pump, or large headspace can increase commercial risk even if the bulk formulation passes stability testing.

Potential controls include:

• Opaque or UV-protective primary packaging
• Low-headspace dispensing systems
• Oxygen-reduced filling
• Antioxidant screening where compatible with the reference formulation
• Light-protective secondary packaging
• Patient instructions that limit heat and light exposure

Any new antioxidant or preservative can affect topical-equivalence risk, irritation, and regulatory comparability.

What excipient changes create the strongest commercial opportunities?

The highest-value opportunities are improvements that solve a known patient or manufacturing problem without changing the product’s therapeutic positioning.

Preservative-reduced or preservative-free systems

Methylparaben supports multidose microbial protection but may be undesirable for some consumers and product-positioning strategies. A preservative-free presentation could use a unit-dose package, airless pump, or validated low-bioburden system. The economic tradeoff is higher packaging cost and more demanding container-closure validation.

A preservative-free version would require robust evidence for:

• Sterility or microbial-control strategy
• In-use contamination resistance
• Container-closure integrity
• Extractables and leachables
• Dose uniformity through the labeled use period

Lower-irritation vehicles

Tretinoin commonly causes erythema, peeling, dryness, and burning. Excipient changes can moderate these effects through improved film formation, controlled release, humectancy, or reduced surfactant exposure. Glycerin level, carbomer concentration, polymer grade, and the choice of solubilization system are the main levers.

A lower-irritation formulation could support premium positioning, but the claim must be supported by comparative clinical data. A different vehicle may reduce irritation while also changing release, absorption, or local tolerability.

Airless and metered dispensing

An airless pump can reduce light and oxygen exposure, limit contamination, and improve dosing consistency. Metered delivery may reduce overapplication, which is relevant for tretinoin because excessive use increases irritation without improving efficacy.

The main barriers are:

• Device compatibility with carbomer gels
• Residual product and dose recovery
• Pump clogging
• Priming behavior
• Tretinoin adsorption to device materials
• Dose consistency near container exhaustion

Improved sensory performance

Acne patients often discontinue topical treatment because of tackiness, pilling, residue, or poor compatibility with cosmetics. A more elegant gel could improve adherence. The formulation developer must control these attributes without introducing oils, solvents, or polymers that destabilize tretinoin or compromise topical-equivalence testing.

When did ZIANA receive FDA approval and lose exclusivity?

The FDA approved ZIANA Gel under NDA 50-803 in December 2006 for acne vulgaris in patients 12 years and older.[2] The product combined two previously known active ingredients in a new fixed-dose topical presentation. It did not receive the five-year new chemical entity exclusivity associated with a novel active molecule.

The likely regulatory protection profile was based on:

• Three-year exclusivity associated with approval of a new clinical investigation, if applicable
• Listed patents in the FDA Orange Book
• Formulation and manufacturing know-how
• Trademark and commercial recognition
• Regulatory difficulty in demonstrating topical equivalence

The three-year exclusivity period would not block all ANDA activity indefinitely. It primarily restricts approval of certain applications relying on the relevant clinical investigations during the protected period. Current market access depends on the Orange Book record, patent status, approved generic products, and any litigation or settlements.

What is the Orange Book status of ZIANA?

ZIANA is an NDA reference product historically associated with Medicis Pharmaceutical Corporation and later Valeant Pharmaceuticals International. FDA Orange Book status should be evaluated using the current electronic Orange Book entry because listed patents, patent-use codes, and marketing status can change over time.[3]

For commercial diligence, the relevant review items are:

Orange Book issue	Strategic significance
Reference listed drug status	Determines the product relied on for an ANDA
Active patent listings	Defines potential Paragraph IV exposure
Patent-use codes	Identifies method-of-use restrictions
Marketing status	Distinguishes active, discontinued, or withdrawn products
Approved generic products	Indicates existing competitive entry
Exclusivity codes	Identifies remaining regulatory barriers

The public ZIANA label does not establish that a current, enforceable patent protects every aspect of the formulation. Patent validity and enforceability require review of the actual Orange Book listing, prosecution history, claim scope, and litigation record.

What Paragraph IV and generic-entry risks affect ZIANA?

The principal generic risk is formulation substitution through an ANDA. A challenger may use different inactive ingredients if the product meets the applicable requirements for pharmaceutical equivalence, bioequivalence, safety, and labeling. For topical products, the development burden can be material because performance depends on local delivery rather than systemic exposure alone.

Potential ANDA evidence can include:

• Comparative physicochemical characterization
• In vitro release testing
• In vitro permeation testing
• Q1 qualitative sameness and Q2 quantitative sameness
• Comparative clinical endpoint studies
• Dermatopharmacokinetic or other locally relevant evidence, where accepted by FDA
• Microbiological and preservative-effectiveness testing

An ANDA applicant using the same inactive ingredients at the same concentrations may reduce formulation risk, but it does not eliminate manufacturing, stability, packaging, or equivalence risk. A differentiated formulation may create stronger commercial value but increases regulatory uncertainty.

What patent and litigation issues matter for ZIANA?

The relevant IP categories are narrow compared with those for a novel small-molecule drug. They may include:

• Fixed-dose clindamycin and tretinoin compositions
• Aqueous or gel vehicles
• Stabilized tretinoin formulations
• Specific concentration ranges
• Methods of treating acne
• Packaging or manufacturing processes
• Combination use with other acne therapies

Patent protection for topical combination products is often weaker than protection for a new chemical entity because active ingredients, therapeutic use, and basic delivery concepts may predate the product. The commercially meaningful question is whether any unexpired claim covers the exact combination, concentration, vehicle, method of use, or manufacturing process used by a proposed entrant.

No biosimilar pathway applies. ZIANA is a small-molecule topical product, so competitive entry occurs through generic-drug pathways rather than through a 351(k) biosimilar application.

How does ZIANA compare with competing acne products?

Product category	Main actives	Excipient opportunity	Competitive pressure
ZIANA	Clindamycin plus tretinoin	Low-irritation gel, light protection, metered dosing	Generic combination products
Clindamycin phosphate gel	Antibiotic alone	Preservative and skin-feel optimization	High generic competition
Tretinoin gel or cream	Retinoid alone	Release control, reduced irritation, cosmetic elegance	High generic competition
Adapalene products	Retinoid-like compound	Gel architecture and tolerability	Branded and generic alternatives
Benzoyl peroxide combinations	Antibiotic or retinoid combinations	Oxidative stability and packaging	Strong acne-category competition
Fixed-dose retinoid and antimicrobial products	Varies	Better adherence and reduced application burden	Competes directly for combination therapy

ZIANA’s main differentiator is convenience from combining an antibiotic and retinoid in one application. Its disadvantages include retinoid irritation, antibiotic-resistance concerns, and the availability of separate or alternative fixed-dose acne products.

What manufacturing and excipient IP barriers remain?

The strongest barriers are likely to be technical rather than absolute legal barriers. A manufacturer must control:

1. Tretinoin light and oxygen exposure.
2. Uniform dispersion in an aqueous carbomer gel.
3. Viscosity across manufacturing lots.
4. Preservative effectiveness through shelf life.
5. Container compatibility and dose recovery.
6. Microbial quality for a multidose topical.
7. Clindamycin and tretinoin assay and degradation products.
8. Scale-up effects from laboratory to commercial mixing.

Excipient suppliers can capture value through high-purity carbomer grades, low-peroxide surfactants, validated preservative systems, UV-protective packaging, and airless dispensing components. The supplier’s defensible position is strongest when the excipient is linked to reproducible performance, regulatory documentation, and a qualified manufacturing process.

What licensing and partnership opportunities exist?

Potential deals are more likely to involve formulation technology, packaging, or regional commercialization than acquisition of a powerful active-ingredient patent estate. Relevant structures include:

• Licensing a low-irritation topical vehicle
• Contract development of a generic ZIANA-equivalent product
• Regional rights for acne combination products
• Co-development of an airless or metered package
• Supply agreements for specialty carbomer or surfactant systems
• Reformulation partnerships for preservative-free delivery
• Private-label dermatology portfolios

A licensee should value the opportunity based on regulatory pathway, product differentiation, manufacturing cost, and remaining market access rather than on ZIANA brand recognition alone.

What generic launch scenarios are commercially realistic?

Standard equivalent gel

This is the lowest-risk route. It uses a conventional aqueous carbomer gel and seeks approval through an ANDA. Price competition is likely to be intense, and the product may have limited differentiation.

Premium tolerability reformulation

A revised gel could emphasize reduced dryness, improved spreadability, or better cosmetic compatibility. This may support a branded or authorized-generic strategy, but comparative clinical and regulatory work increases development cost.

Device-led product

An airless or metered package could improve dosing and stability. The device may create a modest barrier to substitution, although the underlying drug product remains vulnerable to generic competition.

Regional opportunity

Markets with limited availability of fixed-dose clindamycin and tretinoin products may support a regional launch. Regulatory requirements, antibiotic stewardship policies, trademark rights, and local patent status must be assessed separately by country.

Key Takeaways

• ZIANA is a clindamycin phosphate and tretinoin aqueous gel approved in 2006.
• Its core excipient system consists of carbomer 980, glycerin, polysorbate 80, methylparaben, disodium edetate, citric acid, sodium hydroxide, and purified water.
• The main technical challenge is combining a water-compatible antibiotic with light-sensitive, poorly water-soluble tretinoin.
• The strongest formulation opportunities are lower irritation, improved cosmetic feel, preservative-reduced delivery, and airless or metered packaging.
• Generic entry risk is substantial because the product uses established active ingredients and a conventional topical dosage form.
• Patent value depends on current Orange Book listings and claim scope, not on the historical brand name alone.
• No biosimilar pathway applies.
• Licensing opportunities are most credible in formulation technology, packaging, regional commercialization, and specialty excipient supply.
• Manufacturing controls, stability, preservative performance, and topical-equivalence evidence are the principal execution barriers.

FAQs

Is ZIANA a steroid or retinoid product?

ZIANA is not a steroid. It contains the antibiotic clindamycin phosphate and the retinoid tretinoin.

Can a generic ZIANA product use different excipients?

Yes. An ANDA applicant may use different inactive ingredients if the product meets FDA requirements for safety, equivalence, quality, and labeling. Different excipients can increase topical-equivalence and stability risk.

Why is polysorbate 80 important in ZIANA?

Polysorbate 80 helps distribute tretinoin in the aqueous gel and can affect drug uniformity, physical stability, viscosity, and skin tolerability.

Does ZIANA have biosimilar competition?

No. ZIANA is a small-molecule topical drug. Competition proceeds through generic-drug pathways, not the biosimilar pathway.

Which packaging format offers the best opportunity for a ZIANA reformulation?

An airless, light-protective, metered pump offers the strongest combination of contamination control, dose consistency, and photostability potential. Its value depends on device compatibility and demonstrated performance through container exhaustion.

References

1. U.S. Food and Drug Administration. (2006). ZIANA (clindamycin phosphate and tretinoin) gel prescribing information. Medicis Pharmaceutical Corporation.

2. U.S. Food and Drug Administration. (2006). Drugs@FDA: ZIANA NDA 050803. https://www.accessdata.fda.gov/scripts/cder/daf/

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Electronic Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/